medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended a new adalimumab biosimilar for approval in Europe.
The biosimilar – marketed under the brand name of Amsparity – has been shown to have comparable safety and efficacy profiles to its reference product.
It is recommended for the same indications as adalimumab, including rheumatoid arthritis, polyarticular and enthesitis-related juvenile idiopathic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, and psoriatic arthritis.
The biosimilar will be available as a 40 mg solution in a prefilled syringe for adults, while two formulations, 20 mg in a pre-filled syringe and 40 mg/0.8 mL in a vial, will be available for pediatric use.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group